News about "AstraZeneca"

Jacobio Pharma Signs Global Licensing Deal with AstraZeneca for Pan-KRAS Drug

Under the agreement, Jacobio will receive USD 100 million upfront and is eligible for up to USD 1.915 billion in development and commercial milestones, along with tiered royalties on ex-China sales, while AstraZeneca will lead all ex-China development, regulatory and commercial activities for JAB-23E73.

AstraZeneca | 22/12/2025 | By News Bureau

AstraZeneca Secures CDSCO Approval for Breast Cancer Drug in India

AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell and distribute its breast cancer therapy Datopotamab Deruxtecan in India.

AstraZeneca | 20/12/2025 | By Darshana

EU Approves AstraZeneca's Saphnelo for Subcutaneous Self-Administration in Lupus

AstraZeneca has received approval from the European Commission for subcutaneous self-administration of Saphnelo (anifrolumab) using a pre-filled pen for adult patients with systemic lupus erythematosus, in addition to standard therapy.

AstraZeneca | 17/12/2025 | By Darshana

AstraZeneca Unveils Broadest Haematology Data Set Yet at ASH 2025

AstraZeneca is advancing its ambition to transform haematology care with new data from its expanding pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from 6–9 December 2025.

AstraZeneca | 05/12/2025 | By Darshana |  251

Harbour BioMed Advances Global Biotherapeutics Collaboration With AstraZeneca

The alliance focuses on discovering and developing next-generation biotherapeutics, including antibody-drug conjugates and T-cell engagers, by combining the scientific strengths of both companies.

AstraZeneca | 25/11/2025 | By Darshana

Harbour BioMed, AstraZeneca Advance Next-Gen Oncology Biotherapeutics Collaboration

Harbour BioMed has announced an update on the advancement of its global strategic collaboration with AstraZeneca to discover and develop next-generation biotherapeutics in oncology, including antibody-drug conjugates (ADCs) and T cell engagers.

AstraZeneca | 24/11/2025 | By Dineshwori

AstraZeneca Plans USD 2 Billion Manufacturing Investment in Maryland

AstraZeneca will invest USD 2 billion to expand its biologics manufacturing in Maryland, boosting production of cancer, rare disease, and chronic therapies while supporting around 2,600 jobs.

AstraZeneca | 24/11/2025 | By Dineshwori

AstraZeneca, Sun Pharma Announce Second Brand Partnership to Expand Access to Hyperkalaemia Treatment in India

AstraZeneca and Sun Pharma have entered into a second exclusive brand partnership to expand access to Sodium Zirconium Cyclosilicate (SZC) in India for the management of Hyperkalaemia.

AstraZeneca | 17/11/2025 | By Dineshwori |  380

Daiichi Sankyo Initiates First-in-Human Trial for DS3610, a First-in-Class STING Agonist ADC for Advanced Solid Tumours

Daiichi Sankyo has dosed the first patient in a phase 1 clinical trial of DS3610, its investigational STING agonist Antibody Drug Conjugate (ADC), marking a key step in advancing novel immunotherapy approaches for patients with advanced solid tumours.

AstraZeneca | 12/11/2025 | By Dineshwori |  266

Alembic Pharmaceuticals Secures USFDA Approval for Ticagrelor Tablets, 60 mg

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 60 mg. The product is therapeutically equivalent to Brilinta Tablets, 60 mg, from AstraZeneca.

AstraZeneca | 29/10/2025 | By Dineshwori |  138